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Available online 19 May 2008Microarray analysis of formalin-ﬁxed and parafﬁn-embedded (FFPE) tissue seems to be of importance for the
detection of molecularmarker sets in prostate cancer (PC). The compromised RNA integrity of FFPE tissue results
in a high degree of variability at the probe level of microarray data as shown by degradation plot. We tested
methods that reduce the variability by including all probeswithin 300 nucleotides, within 600 nucleotides, or up
to a calculated breakpointwith reference to the 3'-end. Accepted PC pathways such as theWnt signaling pathway
could be observed to be signiﬁcantly regulated within FFPE microarray datasets. The best representation of PC
gene expression, as well as better comparability to meta-analysis and fresh-frozen microarray data, could be
obtained with a 600-nucleotide cutoff. Beyond the speciﬁc impact for PC microarray data analysis we propose a
cutoff of 600 nucleotides for samples for which the integrity of the RNA cannot be guaranteed.
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BreakpointProstate cancer (PC) is the second leading cause of cancer-related
deaths in males [1]. Prostate tumorigenesis is a multistep process that
includes the activation of oncogenes and the loss of tumor suppressor
genes that regulate cell proliferation and apoptosis [2]. PC has a long
latency; precursor lesions that represent intermediate stages between
normal and malignant cells can arise decades before the actual
diagnosis of cancer [3]. The prostate-speciﬁc antigen (PSA) is currently
the best serum indicator for PC,with a sensitivity and speciﬁcity of 72.1
and 93.2%, respectively [4]. However, the lack of additional markers
impedes early diagnosis, choice of treatment, and the prediction of the
clinical outcome.
High-throughput techniques such as microarray analysis of gene
expression in fresh-frozen (FF) tissues have led to the discovery of a set
of molecular markers associated with PC, such as HOXB13 [5], PCGEM1
[6,7], TP63, AMACR [8,9], OR51E2 [10,11], and TMPRSS2 [12]. However,
FF tissue samples do not always provide sufﬁcient morphological
details for a differential diagnosis of precancerous lesions, like severe
prostatic intraepithelial neoplasia, and PC, for which array studies
might be performed. Here a reliable diagnosis can be made only with
formalin-ﬁxed and parafﬁn-embedded (FFPE) tissues. In addition, in
surgical pathology most samples are FFPE.l rights reserved.The ﬁxation process causes cross-linkage of nucleotides (nt) with
proteins and results in covalent modiﬁcation by the addition of mono-
methylol groups to the bases of RNA. In addition to chemical modi-
ﬁcations, RNA samples undergo severe mechanical stresses during
parafﬁn embedding,which affect the average length of transcripts [13].
Although several modiﬁcations in the RNA extraction protocol have
been made to improve RNA quality, the reliability of microarray analy-
sis from FFPE samples continues to be a challenge [14–19]. We have
used PC as an example to establish a general protocol for microarray
analysis of FFPE tissue samples.
To optimize gene proﬁling we used the Paradise reagent system
(Arcturus, Mountain View, CA, USA) in combinationwith a specialized
microarray chip that was speciﬁcally developed to overcome RNA
alterations in FFPE tissue.
We performed a comparative analysis of FFPE tissue microarrays,
with a comparable FF dataset using meta-analysis data, of four pub-
licly available datasets as a reference of PC gene expression [20–23].
A method for microarray analysis was explored that includes only
probes within the ﬁrst 300 or 600 nt or up to a calculated breakpoint
of a transcript. Using this approach we were able to reduce the signal
variability on probe level that is caused by the shortened average
length of RNA from FFPE samples.
In comparison with meta-analysis data we have now shown that
an increase in sensitivity can be observed with the proposed method
in comparison to conventional approaches without “cutoff” without
losing speciﬁcity and thereby increasing the reliability of FFPE
microarray data analysis.
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Standard reference genes (SRG)
Meta-analysis resulted in 1534 SRG. PC-speciﬁc genes such as PSA,
AMACR, TP63, OR51E2, and HOXB13 showed to be signiﬁcantly
regulated in SRG. All the studies that were taken into consideration
for meta-analysis performed microarray analysis on an older version
of Affymetrix chips (HGU95 series). Probes for the marker PCGEM1
were not present on the HGU95 series microarray chip.
Pathway analysis for SRG resulted in 30 signiﬁcantly altered
pathways towhichwe refer to as signiﬁcant reference pathways (SRP).
Degradation plot
A degradation plot shows average expression values for probes
located in intervals of 300 nt starting from the 3'-end of a target mRNA
sequence. The degradation plot for FFPE samples can be divided into
two parts: a steep decline between intervals 300 and 1200 and a
gradual decrease beyond interval 1200 in scaled signal intensity. The
ﬁrst two intervals (300 and 600) have a difference of 0.01 and were
considered suitable distances for the implementation of constant
cutoffs (Fig. 3).
Signiﬁcance analysis of FFPE and FF datasets
Signiﬁcance analysis of microarray (SAM) and mixed-model analysis
(MMA; SAS) were employed for performing signiﬁcance analysis over the
ds_all, ds_300, ds_600, ds_break, and ds_ff datasets. The analysis resulted
in 5871, 6608, 6617, 5530, and 4380 signiﬁcantly regulated genes,Fig. 1. Exemplary Agilent Bioanalyzer proﬁles of RNA from four out of nine FFPE samples and
(B) two individual cancerous samples are shown. (C) The shorter average length of a two step
from a FF sample (right).respectively, for SAM and 2429, 1934, 2199, 309, and 4730 signiﬁcantly
regulated genes, respectively, for SAS statistical methods. Analysis of the
datasets based on a cutoff (ds_300, ds_600, and ds_break) resulted in an
increased number of genes overlapping with the SRG (Table 1). Since the
absolute number of overlapping genes might be misleading, we
introduced the concept of true positive (TP), false positive (FP), true
negative (TN), and falsenegative (FN). For SAMamaximumsensitivityand
speciﬁcity can be observed with the ds_600 dataset (Table 1). Table 2
summarizes PC-speciﬁc genes and their signiﬁcance status within
datasets. SAM for the ds_600 dataset resulted in the maximum number
of PC-speciﬁc genes. In contrast a minimum number of PC-speciﬁc genes
were observed in the SAS ds_break dataset.
Pathway analysis for signiﬁcantly regulated genes
SRG were derived using SAM statistics. In a previous study [39], it
was shown that the comparability of methods (SAM and SAS)
increases at the pathway level. Analyses were performed for the
identiﬁcation of signiﬁcantly altered pathways by implementing
Fisher's exact test for FFPE and FF. Genes found to be signiﬁcantly
regulated for ds_all, ds_300, ds_600, ds_break, and ds_ff with SAM
statistics resulted in 128, 126, 149, 128, and 58 and with SAS statistics
in 32, 36, 42, 2, and 59 signiﬁcantly altered pathways, respectively.
Table S2 lists signiﬁcantly altered pathways with SRG and their
concordance with the FFPE and the ds_ff datasets. We observed a
maximum congruence of 19 of 30 SRP pathways with SAM for the
ds_600 dataset. The congruence between the two statistical methods,
SAS and SAM, was 44% for ds_all and 70% for ds_ff, whereas for the
cutoff datasets it was only between 0 and 26%. Table 3 summarizes
sensitivity and speciﬁcity at different signiﬁcance levels for pathwaysits corresponding β-Actin 3’/5’-ratios. Proﬁles of (A) two individual non-cancerous and
ampliﬁed cRNA from a FFPE sample (left) is set in contrast to a one-step ampliﬁed cRNA
Fig. 2.Work Flow. Probes from Affymetrix chips (HGU133A, U133_X3P, HGU95A and HGU95AV2) were annotated by setting up standalone BLAST against RNA database (downloaded
from NCBI). Based on the relative position with respect to the 3'-end of transcript/gene datasets were divided into 4 groups: ds_all, ds_300, ds_600 and ds_break respectively. SAM
and SAS analysis was performed for the identiﬁcation of signiﬁcantly regulated genes, while Fisher's exact test was performed for pathway signiﬁcance analysis. Meta-analysis was
performed for the four publicly available datasets (see text for detail). The meta-analysis results (SRG and SRP) were used as reference set for the calculations of sensitivity, speciﬁcity
and overlap calculations.
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SRP.
Receiver operator characteristic curve (ROC) analysis at gene and
pathway levels
We performed ROC analysis for signiﬁcantly regulated genes and
pathways so as to identify the dataset on FFPE samples with an
optimal trade-off between sensitivity and speciﬁcity.
Based on the deﬁnitions of TP, FP, TN, and FN for pathway analysis
we performed a ROC analysis for all the FFPE datasets (Fig. 4). For the
initial points on the plot, the other datasets have comparable sensi-
tivity and speciﬁcity but as we move along the x-axis we can observe
that ds_600 excels among all the other datasets between points 0.1(90% speciﬁcity) and 0.35 (65% speciﬁcity). However, all datasets
follow a similar trend beyond point 0.35 on the x-axis.
ROCanalysiswasalsoperformedat thegene level (Fig. S1).Here, unlike
at the pathway level, the ds_ff dataset (area under the curve (AUC) of 78%)
excels over all the other datasets, which range from 60 to 66%.
Analysis of variance (ANOVA)
A 2×2 factorial ANOVA was performed to separate the effects due to
the methods (FFPE and FF) and the effects due to the disease (cancer or
normal). Method-speciﬁc variations seem to be very high for all FFPE
datasets. The implementation of cutoffs (ds_300, ds_600, and ds_break)
resulted in a number of probes that show signiﬁcant method-speciﬁc
effects. The datasets ds_break and ds_all had minimum and maximum
Table 1
Overlap for signiﬁcantly regulated genes obtained with different datasets
ds_all ds_300 ds_600 ds_break ds_ff
Overlapping signiﬁcantly
regulated genes SAM
852 881 935 787 923
Overlapping signiﬁcantly
regulated genes SAS
340 279 304 34 973
Sensitivity SAM (%) 56 57 61 51 60
Sensitivity SAS (%) 22 18 20 2 63
Speciﬁcity SAM (%) 68 68 68 68 62
Speciﬁcity SAS (%) 62 57 60 95 35
If we compare the FFPE datasets with SRG one can observe a clear increase in the number
of genes overlappingwith the implementation of constant cutoffs. The highest overlap can
be observed between constant cutoffs (ds_300 and ds_600), while the smallest number of
overlaps can be observed between the ds_break and the ds_all datasets.
Fig. 3. The degradation plot shows a constant decrease in normalized and scaled signal intensity for all FFPE cancer and non-cancer microarray data as onemoves along the X-axis (nt)
or further away from 3’-end. The ﬁrst two points were chosen for the cut-off ﬁlters (300 cut-off and 600 cut-off). Here, C1, C2, C3, C4 and C5 represent cancer samples while N1, N2, N3
and N4 represent samples from normal tissues.
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Table S3.
Discussion
The gradual 5'-shortening and degradation of RNA from FFPE
samples is a known phenomenon. The low amount of RNA that is
obtained from tissue sections has to be ampliﬁed to generate sufﬁcient
labeled cRNA for microarray hybridization. A T7-based ampliﬁcation
using random primers for the second cDNA synthesis is prone to
shorten RNA fragments even more. To improve the issue of RNA
degradation a specialized microarray chip (Affymetrix, X3P series)
that contains additional probes situated within 300 nt from the 3'-end
of the transcripts can be used to optimize microarray results.
OnanRNAchromatogramof anAgilent bioanalyzer thenarrowshifted
peak of ampliﬁed cRNA from FFPE tissue compared to a FF sample
indicates a shorter average transcript length (Fig. 1C). The gradual
degradation of RNA results in a high variation at the probe level that can
be visualized in a degradation plot by plotting individual signals on the
probe level. This plot shows a steep decline between intervals 300 and
1200 nt in terms of intensity values from 3′ to 5′ (Fig. 3). Due to these
variations not all probes representing a transcript/gene can be considered
for FFPE tissue microarray data analysis. Here, we have considered two
initial intervals (300 and 600) since the difference in average intensities
between these two points is very small.
To reduce the variation within the transcript we implemented
various cutoffs (ds_300, ds_600, and ds_break). A cutoff based on a
constant distance from the 3'-end (ds_300, ds_600) does not take into
consideration that the extent of degradation varies across samples.
Therefore a breakpoint analysis (ds_break) considering the variation
for each transcript across the samples with respect to RNA integrity
might theoretically be better. ANOVA showed a clear decrease in the
number of genes having method-speciﬁc variation, which indicates
that the implementation of probe ﬁlters makes microarray results
more reliable (Table S3).
SAM and SAS analyses were performed in parallel over all FFPE and FF
datasets, for the identiﬁcation of signiﬁcantly regulated genes (Fig. 2). The
number of genes identiﬁed to be signiﬁcantly regulated varied between
the two methods employed. The differences in the numbers of
signiﬁcantly regulated genes obtained by the different methods were
addressed by Wolﬁnger and co-workers, who suggested that these
discrepancies might be due to the different summary methods used [34].
Comparing the signiﬁcantly regulated genes of the different
datasets to SRG, ds_ff had a very high number of genes overlapping
with SAM as well as with SAS analysis (Table 1). For FFPE, the constant
cutoff datasets ds_300 and ds_600 showed an increase in number of
overlapping genes without a loss of speciﬁcity with the implementa-tion of SAM statistics. The ds_600 dataset even had a maximum
number of overlapping genes with SAM analysis. In contrast, with the
ds_break dataset, a decrease in sensitivity and no change in speciﬁcity
were observed. Implementing SAS statistics over the cutoff datasets
resulted in a signiﬁcant decrease in the number of overlapping genes.
In terms of sensitivity and speciﬁcity, a marginal decrease of 2 and 4%
was observed for ds_600 and ds_300, respectively. One of the
potential reasons for the decrease in sensitivity with SAS could be
that the number of probes per transcript/gene was not sufﬁcient for
performing MMA. The larger decline (20%) in sensitivity for ds_break
can be explained by the number of probes per transcript/gene that
vary across the samples. A second reason could be that the SRG was
obtained using SAM statistics. Hence, it has better concordance with
the genes obtained with signiﬁcance analysis using SAM.
ROC analysis was also performed at the gene level for the FF and
FFPE datasets. The ds_ff dataset excels over all other datasets by
having an AUC of 78% compared to FFPE datasets, which ranges
between 60% for ds_300 and 65.8% for ds_all. On the x-axis between
points 0 and 3.8, all FFPE datasets have a similar trend for sensitivity
and speciﬁcity trade-off (Fig. S1).
In the results from the ds_600 dataset all PC-speciﬁc genes such as
PSA, PCGEM1, TP63, OR51E2, TMPRSS2, AMACR, and HOXB13were found
to be signiﬁcantly regulated (Table 2).
Analysis using SAM and SAS differed in terms of number of pathways
shown to be signiﬁcantly affected. The differences between the two
methods at the pathway level might be due to the fact that the number of
signiﬁcantly altered pathways is directly proportional to the number of
signiﬁcantly regulated genes. However,most of the signiﬁcantly regulated
pathways obtained with SAS were common to SAM. Compared to SRP,
ds_all and ds_ff show better congruence between the methods than the
datasets ds_300, ds_600, and ds_break. A previous study [39] has
Table 2
PC-speciﬁc genes and their signiﬁcance and nonsigniﬁcance across all datasets
Gene ds_all ds_300 ds_600 ds_break ds_ff SRG
SAM SAS SAM SAS SAM SAS SAM SAS SAM SAS SAM
PSA S S S S S S S NS NS NS S
AMACR S S NA NA S S S S S S S
PCGEM1 S NS S S S S S NS NS NS NA
TP63 NS NS S NS S NS NS NS S S S
OR51E2 S S NS NS S NS S NS S S S
TMPRSS2 S S NS NS S NS S NS S NS NS
HOXB13 S S NS NS S NS S NS S S S
The same number of markers can be observed with ds_all and ds_ff datasets. However,
with the implementation of cutoff (ds_600 and ds_break) we are not losing any marker
genes and yet we are improving the sensitivity for the ds_600 dataset (see text for
details). S, signiﬁcantly regulated with the respective analysis; NS, not signiﬁcantly
regulated with the respective analysis; NA, not considered for the respective analysis.
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gene expression analysis as well as signiﬁcance analysis by different
statistics (SAM and MMA) improves at the pathway level. Table S4
contains the list of pathways that were almost 100% congruent with SAM
and SAS analyses and their signiﬁcance status for FFand FFPE datasets. For
this set of pathways aminimalmethod-dependent effect can be observed
except for the ds_break dataset. Due to the variable number of probes per
transcript/gene across the samples SAS analysis could not be implemen-
ted. It can be concluded that the method-speciﬁc effect observed for SRP
essentially exists. To compare all FFPE datasets, we considered SAM only.
At the pathway level, an increase in sensitivity, as well as
speciﬁcity, can be observed for the ds_300 and ds_break datasets
from the signiﬁcance level (p-value) of 0.01 to 0.03 with respect to
ds_all. Beyond the signiﬁcance level of 0.03, one can observe a slight
decline in the sensitivity and speciﬁcity percentages for ds_300 and
ds_break datasets. It is with the ds_600 dataset that a maximum
increase in sensitivity can be observed at all signiﬁcance levels.
Compared with SRP a maximum overlap of 19 pathways can be
obtained with SAM on the ds_600 dataset. The other datasets (ds_all,
ds_300, and ds_break) resulted in 16,16, and 15 overlapping pathways,
respectively. To reduce the false positive rate, our interestwas to obtain
an optimal trade-off for sensitivity and speciﬁcity and not the
maximum number of overlapping pathways. For FFPE datasets, ROC
analysis at the pathway and gene levels did not reveal a signiﬁcant
difference in AUC (Figs. 4 and S1); although a slight increase in AUC at
the pathway level indicates that the dataset ds_600 has a slight edge
over all the other FFPE datasets.
Pathways suchasWnt, androgen signaling [40], p53 signaling [41], and
adenine monophosphate synthesis [42], which have all been shown to
playa role inPCdevelopmentandprogression, are signiﬁcantwithall FFPE
datasets. Aberrant Wnt signaling has been shown to be important in
prostatic tumorigenesis and the level of expression ofWnt pathwaygenes
mightbeprognosticallyvaluable [43]. Thebest representationofpathways
was obtained with the ds_600 and ds_ff datasets. Fig. 5 shows the
signiﬁcantly up-regulated genes from the ds_600 and ds_ff datasets
within the Wnt pathway, including Frizzled, GSK3, Groucho, HDAC1, GBP,Table 3
Sensitivity and speciﬁcity at the pathway level
Sensitivity Speciﬁcity Sensitivity Speciﬁcity
Signiﬁcance level (p value) 0.01 0.02
ds_all 40 86.7 43.3 84.3
ds_300 40 90 46.7 85.3
ds_600 50 84 56.7 78.5
ds_break 46.7 88.6 46.7 85.5
ds_ff 20 92.4 26.7 92.4
Sensitivity and speciﬁcity values at different signiﬁcance levels across all datasets are show
sensitivity at the cost of speciﬁcity. It is only with the ds_600 dataset that we observe an inandNLK in common between the two datasets. AdditionalWnt-activated
genes such as CyclinD1 and PPARδwere obtained with ds_600.
In summary, the ability to use FFPE tissue samples for comparable
microarray analysis would be a major advancement for retrospective
studies of samples with a clinical follow-up. The improvement of
isolation protocols and the approach for specialized microarray plat-
forms enable researchers to generate expression proﬁles based on small
amounts of RNA from FFPE samples with a relatively poor 3′ to 5′ ratio.
Optimizing the analysis according to the integrity of RNA by
applying a ﬁlter at probe level improves the efﬁcacy for FFPE
microarray data analysis.
In theory ds_break would be the most optimal cutoff method to
reﬂect RNA integrity status at probe level, althoughwe did not observe
it as the best method in our present study. This leads us to believe that
the statistical method behind breakpoint analysis certainly has the
potential for being improved with regard to microarray analysis.
Several lines of evidence have now been provided that the best
representation of PC as well as better comparability to standard
reference genes and fresh-frozen microarray data can be obtained
with the ds_600 dataset of FFPE. We therefore propose a constant
cutoff of 600 nt to improve microarray data analysis for FFPE samples
for which the integrity of the RNA cannot be guaranteed.
Materials and methods
Tissue and specimens
FFPE and FF samples of human prostate adenocarcinoma were collected from
patients at the time of radical prostatectomy at the University Hospital Heidelberg and
theNephrology Center, HannoverschMünden. After radical prostatectomy, independent
tissues were either snap-frozen in liquid nitrogen or ﬁxed in 4% buffered formalin (pH
7.3) and embedded in parafﬁn within 24 h. FFPE samples were collected between 2003
and 2005 and stored at room temperature for at least 1 year before further processing. FF
tissue including nine primary cancers and eight noncancerous tissueswere examined. In
addition FFPE tissues of ﬁve primary cancers and four noncancerous areas were
analyzed. Cancerous tissue was graded according to the Gleason scoring system by a
pathologist (H.-J.G.). Gleason scores of primary tumors ranged between 6 and 8.
Tissue sectioning
Thirty to forty FF sections of 5 μmwere cut at 20 °C under RNase-free conditions,
transferred to an Eppendorf tube kept on ice, and snap frozen in liquid nitrogen. FFPE
sections were cut at 5 μm and transferred to glass slides. Slides were dried at 37 °C for
1 h and stored at 80 °C until further use. The ﬁrst, themiddle, and the last sections of FF
and FFPE were stained by H&E to corroborate the diagnosis.
RNA isolation, quality control, ampliﬁcation, and labeling of frozen tissue samples
Tissue was taken up in guanidinium thiocyanate and homogenized by pipetting up
and down. Further isolation was according to the protocol of Chomczynski and Sacchi
[24]. RNA quality and quantity were analyzed with an RNA 6000 Nano LabChip on the
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). Samples were labeled with
the One-Cycle Target Labeling Assay (Affymetrix, Santa Clara, CA, USA). Brieﬂy, 2.5 μg of
total RNA was used to generate double-stranded (ds) cDNA. The ds cDNA was puriﬁed
with the Sample Cleanup Module (Affymetrix), and biotin-labeled cRNAwas generated
with the GeneChip IVT Labeling Kit (Affymetrix). Ten micrograms of fragmented cRNA
was hybridized to the GeneChip Human Genome U133A Array (Affymetrix).
Fragmentation, hybridization, washing, and staining were conducted according to
the manufacturer's recommendations. Labeled probes were denatured at 99 °C forSensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity
0.03 0.04 0.05
46.7 87 53.3 87.4 53.3 71.2
53.3 90.7 53.3 90.8 53.3 69.7
56.7 84.4 63.3 84.8 63.3 67.2
50 89 50 89 50 70
26.7 95.4 26.7 95.4 26.7 86
n. With the implementation of constant cutoffs we can observe a clear increase in the
crease in sensitivity at different signiﬁcance levels.
Fig. 4. ROC analysis at pathway level. ROC plots for FFPE and FF datasets, ds_all, ds_300,
ds_600, ds_break and ds_ff having AUC of 85.7, 87.2, 88.2, 87.4 and 83.7% respectively,
are shown. Although the AUC for datasets does not differ to a very great extent, one can
observe a slight increase with the implementation of cut-offs.
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performed on a GeneChip Fluidics Station 450 (Affymetrix). Data were acquired by a
GeneChip Scanner 3000 (Affymetrix).Fig. 5. The canonicalWnt signaling pathway.Wnt signaling was shown to be signiﬁcantly alte
genes differ slightly. Marked in gray are the signiﬁcantly regulated genes resolved from the d
gray represents genes signiﬁcantly regulated only with ds_ff. Hatched boxes indicate genes
using Ingenuity Pathways Analysis (Ingenuity Systems, www.ingenuity.com).RNA isolation, quality control, ampliﬁcation, and labeling of FFPE tissue samples
Theextraction and ampliﬁcation ofRNA fromFFPE sampleswere handled according to
the protocol of the Paradise reagent system (Arcturus). Brieﬂy, 5-μm sections were
deparafﬁnized, rehydrated, and stainedwith Paradise staining solution. Tumorous areas of
30 sectionswere dissectedwith a scalpel and transferred into a 0.5-ml tube. The tissuewas
digested with Pro K mix overnight at 50 °C. Total RNA was isolated with MiraCol
puriﬁcation columns and contaminating DNAwas digested with DNase mix for 20 min at
room temperature. RNA quality and quantity from FFPEwere evaluatedwith a SYBR green
qRT-PCR assay for detection of β-actin mRNA as described in the Paradise Reagent System
User Guide versionB (Arcturus). The ampliﬁcationwas carried out using the LightCycler 2.0
system (Roche Diagnostics, Mannheim, Germany). Two amplicons of β-actin mRNAwere
ampliﬁed with primers (BioSpring, Frankfurt, Germany) described in the QC protocol
(Arcturus). The RNA quantity was calculated based on the 3′ amplicon of β-actin
considering the standard curve of a serial dilution starting from 10 μg RNA.
The 3′/5′ ratio can be used to estimate the integrity and the degree of degradation
of RNA that correlates with the bioanalyzer proﬁles [25]. Figs. 1A and B show repre-
sentative bioanalyzer proﬁles from two noncancerous (Fig. 1A) and to two cancerous
(Fig. 1B) FFPE prostate samples with the corresponding 3′/5′ β-actin ratio used in this
study. FFPE samples chosen for further processing had ratios between 1 and 6.3. For the
four noncancerous and the ﬁve cancerous samples the ratios were 1.1, 4.6, 1.9, and 2.4
and 2.4, 3.4, 2.8, 1.6, and 6.2, respectively.
An amount of 6–10 ng total RNAwas ampliﬁedwith the Paradise reagent system by one
and one-half rounds of ampliﬁcation. Biotin-labeled cRNA was generated by the Enzo
BioArray High Yield RNA transcript labeling kit (Enzo Life Sciences, Farmingdale, NY, USA).
Human U133A X3P GeneChips (Affymetrix) were used for hybridizing 10 μg of
fragmented cRNA. Fragmentation, hybridization, washing, and staining were performed
in the same fashion as with the FF samples.
Probe annotation
CustomCDF (chip deﬁnitionﬁle) improves the results ofmicroarrayanalyses [26]. To
annotate the probes for the generation of custom CDF, a standalone BLAST search wasred with all cutoff datasets for FFPE and FF even if the numbers of signiﬁcantly regulated
s_600 and the ds_ff datasets. Genes in dark gray are represented only by ds_600. Light
that were signiﬁcantly regulated with both ds_ff and ds_600. This ﬁgure was generated
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arrays versus the annotated Homo sapiens RNA database downloaded from the National
Center for Biotechnology Information, ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/RNA/
(downloaded on January 7, 2007). Standalone BLAST results were parsed using an in-
house Perl script for unique gene-speciﬁc probes and probe position with respect to the
3'-end of the transcript.
Degradation plot
A degradation plot provides qualitative information regarding the degree of degra-
dation of RNA. The degradation plot was made by ﬁrst scaling all probes representing a
gene in a normalized dataset per sample to 1. As a second step, the average was taken
over all probes falling in consecutive intervals of 300 nt from the 3'-end.
Microarray data preprocessing
After the probes were mapped to a unique gene along with their positions with
respect to the 3'-end, the microarray data were normalized by VSN (variance
stabilization and normalization) [27] and further analyzed by including either all
probes of a gene or only probes located within the ﬁrst 300 nt, within the ﬁrst 600 nt, or
up to a calculated breakpoint (see Breakpoint analysis). Only genes that were
represented by at least four probes were included. A schematic representation of the
work ﬂow is shown in Fig. 2.
This procedure resulted in the followingdatasets considered for theanalysis: all probes
(ds_all), all probeswithin theﬁrst 300 nt from the 3'-end (ds_300) or all probeswithin the
ﬁrst 600 nt from 3′ end (ds_600), and all probes up to a calculated breakpoint (ds_break).
The same approach as for ds_all was applied to data from fresh-frozen samples
(ds_ff) and to published datasets (Table S1).
Breakpoint analysis
Identiﬁcation of an unknown breakpoint in a linear regression relationship is of
importance in statistical analysis. Probe sets were subjected to breakpoint analysis
based on the F test [28]. The R package Strucchange implements breakpoint analysis as
suggested by Zeileis and co-workers [28].
Let us consider a standard linear regression model,
yi ¼ xTi bi þ Ai i ¼ 1; N ; nð Þ; ð1Þ
where at point i, yi is the observation of the dependent variable, xi=(1, xi2, …, xik)T is a
k×1 vector of the observations of the independent variables, and μi are independently
and identically distributed with 0 mean and variance σ2. The βi are the components of a
k×1 vector of regression coefﬁcients.
Here, we formulate a null hypothesis that there is no ﬂuctuation or breakpoint in
the data,
H0 : bi ¼ b0 i ¼ 1; N ;nð Þ; ð2Þ
against the alternate hypothesis that coefﬁcient vector varies over xi, which can be
modeled as
bi ¼ bA 1V iV i0ð ÞbB i0 b iVnð Þ ;

where i0 is some change at interval (k, n  k). Chow was the ﬁrst to suggest such a test
on structural change in case the (potential) change point i0 is known [29]. He proposed
to ﬁt two separate regressions for the two subsamples deﬁned by i0 and to reject
whenever the following is too large:
Fi0 ¼ Uˆ
T
Uˆ  eˆT eˆ
eˆT eˆ= n 2kð Þ
where eˆ=(UˆA, UˆB)T are the residuals from the full model, the coefﬁcients in the
subsamples are estimated separately, and Uˆare the residuals from the restricted model,
where the parameters are ﬁtted just once for all observations. The test statistic Fi0
has an asymptotic χ2 distribution with k degrees of freedom and under the assump-
tion of normality Fi0/k has an exact F distributionwith k and (n − 2k) degrees of freedom.
The major drawback of this “Chow test” is that the change point has to be known in
advance.
To overcome this drawback, the supF test was developed [30]. The supF test largely
avoids the difﬁculties associated with the standard F test with known breakpoints by
searching over all possible breakpoints in the data.
Microarray data analysis
Microarray data for FFPE samples from ﬁve cancers and four normal patients and FF
samples for nine cancer and eight normal patients were analyzed.
Microarray CEL ﬁles were imported to R statistical package version 2.4.0 [31] using R
Affy package version 1.6 and subjected to VSN. A correlation study was performed and
led to the exclusion of one noncancerous FFPE sample that was an outlier with an RNA
ratio of 4.6.After normalization, the different ﬁlters resulted in the subsequent datasets (ds_all,
ds_300, ds_600, ds_break, and ds_ff). The median was used as a statistical measure
for combining values from different probes for the same transcript into a single value also
known as the summarymethod. Signiﬁcance analysiswas performed using the bioconductor
package SAMR, which implements SAM statistics [32] in R. A cutoff of 5% false discovery rate
(FDR) [33] was applied to identify signiﬁcantly regulated genes.
In a second approach MMA was applied in parallel to the normalized datasets
ds_all, ds_300, ds_600, ds_break, and ds_ff using SAS [34] for identiﬁcation of signiﬁ-
cantly regulated genes.
Two way ANOVA was applied over normalized datasets for the evaluation of
comparability for FF and FFPE datasets.
Meta-analysis
PCmicroarray expression proﬁling has been performed bymany laboratories. Thus, one
might integrate the different studies to reduce the number of false positive ﬁndings due to
samplingerrors.Meta-analysiswasperformedonpublishedPCmicroarraydata (Table S1) by
employing effect size methods as suggested by Choi and co-workers [35] and implemented
in the GeneMeta version 1.4 Bioconductor package. The effect sizemethod provides efﬁcient
modeling of datasets for addressing interstudy variations. GeneMeta employs SAM statistics
for identiﬁcationof signiﬁcantly regulatedgenes. A FDRcutoff of 5%wasapplied. Signiﬁcantly
regulated genes from the meta-analysis were deﬁned as standard reference genes.
Pathway analysis
Fisher's exact test [36] was employed to identify pathways that are most likely to be
affected by expression changes of the signiﬁcantly regulated genes. Five hundred twenty-
four pathways from the Molecular Signatures Database (Broad Institute, Cambridge, MA,
USA; also including KEGG pathways) [37,38] were considered for pathway analysis.
Sensitivity and speciﬁcity calculations for FFPE datasets
For a given dataset, a set of genes is considered to be TP if the genes are signiﬁcantly
regulated in both SRG and the dataset under consideration. Similarly, we deﬁned FP genes
as the set of genes that are signiﬁcantly regulated in one of the FFPE datasets but not
signiﬁcantly regulated in SRG. Genes that are not signiﬁcantly regulated in either SRG or
the FFPE dataset are considered TN and genes that were signiﬁcantly regulated in SRG but
not signiﬁcantly regulated in FFPE analysis were selected as FN. Using these terms,
sensitivity=TP/(TP + FN) and speciﬁcity=TN/(TN+FP) were calculated for all datasets.
A similar approach was applied for calculations of sensitivity and speciﬁcity at the
pathway level with a difference that gene sets were replaced by pathway sets.
ROC
ROC isaplot thathas sensitivityon they-axis and1− speciﬁcityon thex-axis. Essentiallya
ROC plot represents the true positive rate vs the false positive rate. The ROC of a classiﬁer
(signiﬁcantly regulated genes obtained by application of datasets) shows its performance as a
trade-off between sensitivity and sensitivity. Comparing different methods, the AUC shows
the efﬁcacy of a method. The greater the AUC, the better the method is.Acknowledgments
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